Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_assertion type Assertion NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_head.
- NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_assertion description "[We therefore further compared the antithrombotic (Benefit: dose required for 50% inhibition of fibrinogen decrease: ED50) and hemorrhagic (Risk: minimum dose required for significant prolongation of bleeding time) effects of MR-33 and LMW-heparin in the thromboplastin-induced DIC model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_provenance.
- NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_assertion evidence source_evidence_curated NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_provenance.
- NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_assertion SIO_000772 9134660 NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_provenance.
- NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_assertion wasDerivedFrom ctd_human-20130708 NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_provenance.
- NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_assertion wasGeneratedBy ECO_0000218 NP15309.RAC-DFJD3fyCFaZbCAN_3aUDUxO5k7opDL-PKEjFdcFS8130_provenance.